When you are transitioning a patient, be sure they understand what follow-up they will receive and who and when they can call should they have questions. If you and your colleagues have executed a robust biosimilars transition program, you should have mitigated most of the risk of nocebo. However, as with all biologics,  at some point a patient may not respond to medication. This could be for a number of reasons all of which should be considered. Loss of response could be the expected loss of response based on the patient’s history.